Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Wendt

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of Medicinal Chemistry|June 1, 2001
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasiaM D Meyer, R J Altenbach, H Bai, et al.
Journal of Medicinal Chemistry|October 10, 2008
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteinsCheol-Min Park, Milan Bruncko, Jessica Adickes, et al.
Journal of Medicinal Chemistry|November 5, 1997
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasiaM D Meyer, R J Altenbach, F Z Basha, et al.
Journal of Medicinal Chemistry|February 3, 2006
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivoMichael D Wendt, Wang Shen, Aaron Kunzer, et al.
Journal of Medicinal Chemistry|January 30, 2007
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xLMilan Bruncko, Thorsten K Oost, Barbara A Belli, et al.
Chemical Biology & Drug Design|July 17, 2007
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategiesJeffrey R Huth, Chang Park, Andrew M Petros, et al.
Journal of Medicinal Chemistry|April 4, 2017
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain InhibitorsLe Wang, John K Pratt, Todd Soltwedel, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
Nature|May 20, 2005
An inhibitor of Bcl-2 family proteins induces regression of solid tumoursTilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of Medicinal Chemistry|June 1, 2001
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasiaM D Meyer, R J Altenbach, H Bai, et al.
Journal of Medicinal Chemistry|October 10, 2008
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteinsCheol-Min Park, Milan Bruncko, Jessica Adickes, et al.
Journal of Medicinal Chemistry|November 5, 1997
Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasiaM D Meyer, R J Altenbach, F Z Basha, et al.
Journal of Medicinal Chemistry|February 3, 2006
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivoMichael D Wendt, Wang Shen, Aaron Kunzer, et al.
Journal of Medicinal Chemistry|January 30, 2007
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xLMilan Bruncko, Thorsten K Oost, Barbara A Belli, et al.
Chemical Biology & Drug Design|July 17, 2007
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategiesJeffrey R Huth, Chang Park, Andrew M Petros, et al.
Journal of Medicinal Chemistry|April 4, 2017
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain InhibitorsLe Wang, John K Pratt, Todd Soltwedel, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
Nature|May 20, 2005
An inhibitor of Bcl-2 family proteins induces regression of solid tumoursTilman Oltersdorf, Steven W Elmore, Alexander R Shoemaker, et al.
ACS Medicinal Chemistry Letters|October 16, 2020
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> InhibitorLe Wang, George A Doherty, Andrew S Judd, et al.
Pageof 10